METASTATIC PROSTATE CARCINOMA

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long men can stay on treatment and how well it controls the cancer. Par…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy to men with advanced prostate cancer that has spread and has not been treated before. The goal is to see if this hormone therapy can lower PSA levels more effectively…

This study tests different combinations of approved drugs to see which works best for men with advanced prostate cancer that has stopped responding to hormone therapy. About 200 men will receive either a standard hormone-blocking combo or that combo plus an immunotherapy or chemo…

This study tests whether adding cediranib to olaparib works better than olaparib alone for men with a type of advanced prostate cancer that has spread and stopped responding to hormone therapy. About 90 men will take part. The goal is to see if the combination can slow cancer gro…

This study looks at whether men with metastatic prostate cancer that has responded extremely well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal, potentially improving quality o…

This study tests three treatment options for men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair defects. Participants receive either abiraterone (a hormone blocker), olaparib (a targeted drug), or both together. The goal is to…

This study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA …

This study is testing if adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better for treating advanced prostate cancer that has spread and stopped responding to hormone therapy. It compares this new combination to the standard treatmen…

This study looks at how certain hormone therapies for advanced prostate cancer might affect thinking skills like memory and attention. About 100 men who are already on these treatments will take thinking tests and have brain scans to see if there are changes. The goal is to under…

This study is for men with prostate cancer that has spread and is no longer responding to hormone therapy. Researchers collect tissue, blood, and urine samples to study gene changes and look for biomarkers. The goal is to better understand how the cancer behaves and how patients …

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …